6:43 PM · 7 December 2021

Novavax gains after unconfirmed news of drug authorization in Europe

The biotech company Novavax (NVAX.US) has risen more than 20% during today's trading session on Wall Street, following news from the head of the European Medicines Agency (EMA). As reported by Reuters, the head of the EMA said that a vaccine being developed by US company Novavax will be authorized "in the very near future". The company's vaccine has so far been authorized in Indonesia and the Philippines. During clinical trials in the US, UK and Mexico, the NVX-CoV2373 vaccine has demonstrated over 90% efficacy. The company announced on 2 December that it is able to produce Omicron variant vaccines as early as January 2022. 

Novavax (NVAX.US) stock, D1 interval. From the perspective of technical analysis, the company is moving in a descending triangle formation. Currently, the price is testing the resistance set by the 200 EMA (yellow line). If the demand side manages to break above this limit, it will be possible to test the local peak near $229 per share. If the upside is stopped, the key support remains the lower limit of the descending triangle formation at $122.5 usd per share. Source: xStation 5

24 July 2026, 6:55 PM

Daily Summary: Equities Diverge as Tech Lags, Europe Rallies on Earnings & PMIs (24.07.2026)

24 July 2026, 3:22 PM

US OPEN: Nasdaq hits 1-month low! Geopolitics bring AI trade down!

24 July 2026, 12:37 PM

Market Wrap: European Stocks Are Trying to Rebound as the Week Comes to an End💡

24 July 2026, 11:23 AM

Alphabet shares are down 22% from their all-time high 🚩 Is Google ready to resume its bull run?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits